An update clinical application of amniotic fluid-derived stem cells (AFSCs) in cancer cell therapy and tissue engineering.
Recent studies have elucidated that cell-based therapies are promising for cancer treatments. The human amniotic fluid stem (AFS) cells are advantageous cells for such therapeutic schemes that can be innately changed to express therapeutic proteins. HAFSCs display a natural tropism to cancer cells in vivo. They can be useful in cancer cells targeting. Moreover, they are easily available from surplus diagnostic samples during pregnancy and less ethical and legal concern are associated with the collection and application than other putative cells are subjected. This review will designate representatives of amniotic fluid and stem cell derived from amniotic fluid. For this propose, we collect state of human AFS cells data applicable in cancer therapy by dividing this approach into two main classes (nonengineered and engineered based approaches). Our study shows the advantage of AFS cells over other putative cells types in terms differentiation ability to a wide range of cells by potential and effective use in preclinical studies for a variety of diseases. This study has shown the elasticity of human AFS cells and their favorable potential as a multipotent cell source for regenerative stem cell therapy and capable of giving rise to multiple lineages including such as osteoblasts and adipocyte.
a Women?s Reproductive Health Research Center , Tabriz University of Medical Sciences , Tabriz , Iran.|b Department of Molecular Medicine, School of Advanced Medical Science , Tabriz University of Medical Science , Tabriz , Iran.|c Student Research Committee , Tabriz University of Medical Sciences , Tabriz , Iran.
Shiva
S
Gholizadeh-Ghaleh Aziz
d Department of Clinical Sciences , Faculty of Veterinary Medicine, University of Tabriz , Iran.
Ezzatollah
E
Fathi
e Department of Clinical Biochemistry , Tabriz University of Medical Science , Tabriz , Iran.
Mohammad
M
Rahmati-Yamchi
f Drug Applied Research Center , Tabriz University of Medical Sciences , Tabriz , Iran.
Abolfazl
A
Akbarzadeh
a Women?s Reproductive Health Research Center , Tabriz University of Medical Sciences , Tabriz , Iran.|b Department of Molecular Medicine, School of Advanced Medical Science , Tabriz University of Medical Science , Tabriz , Iran.
Zahra
Z
Fardyazar
a Women?s Reproductive Health Research Center , Tabriz University of Medical Sciences , Tabriz , Iran.|f Drug Applied Research Center , Tabriz University of Medical Sciences , Tabriz , Iran.|g Department of Anatomical Sciences , Faculty of Medicine, Tabriz University of Medical Sciences , Tabriz , Iran.
Maryam
M
Pashaiasl
D000653:Amniotic Fluid / Q000166:cytology*; D000818:Animals; D002454:Cell Differentiation; D064987:Cell- and Tissue-Based Therapy / Q000379:methods*; D006801:Humans; D009369:Neoplasms / Q000473:pathology / Q000628:therapy*; D013234:Stem Cells / Q000166:cytology*; D023822:Tissue Engineering / Q000379:methods*
Human amniotic fluid stem (hAFS) cells; cancer cells targeting; cancer therapy; cell-based therapies